Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
September 30, 1998
Study Completion Date
April 30, 2004
Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG
irofulven
Trial Locations (1)
20892
Medicine Branch, Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00019552 - Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer | Biotech Hunter | Biotech Hunter